Compare Bristol-Myers Squibb Co (BMY) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Bristol-Myers Squibb Co trades at $57.17 (market cap $116.30B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.03. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Bristol-Myers Squibb Co nearer its low. Which is the better fit depends on your goals.
| BMY | QQQE | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $62.37 | $122.72 |
52-Week Low | $42.60 | $96.06 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQE trades at $119.15, down 1.21% on the day, with technical indicators showing a neutral overall signal. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential inclusion in the Nasdaq-100, which could drive additional ETF inflows.
The equal-weight strategy offers defensive positioning during market rotations, though key financial ratios remain unavailable for analysis. Risks include market volatility and concentration in growth stocks. Analyst sentiment appears mixed with equal buy/sell signals, suggesting balanced institutional views on near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
